Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease

Circulation

Volumn 96, Issue 5, 1997, Pages 1424-1431

  Carter, Angela M ^a,c   Ossei Gerning, Nicholas ^a   Wilson, Ian J ^b   Grant, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Molecular biology; Myocardial infarction; Platelets; Stenosis

Indexed keywords

FIBRINOGEN; GLYCOPROTEIN IIB;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DNA POLYMORPHISM; FEMALE; FIBRINOGEN BLOOD LEVEL; GENOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOSIS;

EID: 0030882209     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.5.1424     Document Type: Article

References (38)

1. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol. 1994;24:1591-1601.
2. Peerschke EI. Stabilization of platelet-fibrinogen interactions is an integral property of the glycoprotein IIb-IIIa complex. J Lab Clin Med. 1994;124:439-446.
3. Harker LA, Hanson SR. Platelet factors predisposing to arterial thrombosis. Baillieres Clin Haematol. 1994;7:499-522.
4. Fitzgerald DJ. Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators. Am J Cardiol. 1991;68:51B-57B.
5. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
6. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo JC. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
7. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-641.
8. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84:613-617.
9. Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JW. Ischemic heart disease and platelet aggregation: the Caerphilly Collaborative Heart Disease Study. Circulation. 1991;83: 38-44.
10. Bolibar I, Kienast J, Thompson SG, Matthias R, Niessner H, Fechtrup C. Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease: the ECAT Angina Pectoris Study Group. Am Heart J. 1993;125:1601-1605.
11. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995;15:1263-1268.
12. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73:374-379.
13. Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis. 1990;85:169-173.
14. Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, Hiroki T, Arakawa K. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis. 1989;77: 209-213.
15. Bini A, Kudryk BJ. Fibrinogen in human atherosclerosis. Ann N Y Acad Sci. 1995;748:461-471.
16. McGill DA, Ardlie NG. Abnormal platelet reactivity in men with premature coronary heart disease. Coron Artery Dis. 1994;5: 889-900.
17. Ghaddar HB, Cortes J, Salomaa V, Kark JD, Davis CE, Folsom AR, Heiss G, Stinson V, Wu KK. Correlation of specific platelet activation markers with carotid arterial wall thickness. Thromb Haemost. 1995;74:943-948.
18. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
19. Baumann RE, Henschen AH. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions A alpha 312 and B beta 448. Blood. 1993; 82:2117-2124.
20. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen Bβ 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arterioscler Thromb Vasc Biol. 1997;17:589-594.
21. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou JP, Scarabin PY, Bara L, Green F, Cambien F. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM Study: Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation. 1996;93:440-449.
22. 33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989;83:1778-1781.
23. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-1094.
24. Nomenclature and criteria for diagnosis of ischemic heart disease: report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 1979;59:607-609.
25. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol. 1997;17:33-37.
26. Clauss A. Gerinnungsphysiologishce Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
27. Unkelbach K, Kalb R, Santoso S, Kroll H, Mueller-Eckhardt C, Kiefel V. Genomic RFLP typing of human platelet alloantigens Zw(PlA), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol. 1995; 89:169-176.
28. A polymorphism in young men with myocardial infarction. Lancet. 1996;348:485-486. Letter.
29. Fowkes FG, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GD. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet. 1992;339:693-696.
30. Humphries SE, Ye S, Talmud PJ, Bara L, Wilhelmsen L, Tiret L. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A β-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe: evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol. 1995;15:96-104.
31. de Maat MPM, de Knijff P, Green FR, Thomas AE, Jespersen J, Kluft C. Gender-related association between β-fibrinogen genotype and plasma fibrinogen levels and linkage disequilibrium at the fibrinogen locus in Greenland Inuit. Arterioscler Thromb Vasc Biol. 1995;15:856-860.
32. Baumann RE, Henschen AH. Linkage disequilibrium relationships among four polymorphisms within the human fibrinogen gene cluster. Hum Genet. 1994;94:165-170.
33. Green F, Hamsten A, Blomback M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost. 1993;70:915-920.
34. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993;14:8-17.
35. Goldschmidt-Clermont PJ, Shear WS, Schwartzberg J, Varga CF, Bray PF. Clues to the death of an Olympic champion. Lancet. 1996;347:1833. Letter.
36. DiMinno G, Silver MJ, Cerbone AM, Rainone A, Postiglione A, Mancini M. Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis. 1986;6:203-211.
37. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
38. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1996;343:881-886.